IR@PKUHSC  > 北京大学基础医学院  > 细胞生物学系
学科主题基础医学
A Minority Subpopulation of CD133+/EGFRvIII+/EGFR- Cells Acquires Stemness and Contributes to Gefitinib Resistance
Liu, Xu-Jie1; Wu, Wen-Tao1; Wu, Wei-Hua1; Yin, Feng2; Ma, Si-Hai3; Qin, Jia-Zhen4; Liu, Xiu-Xiu1; Liu, Yi-Nan1; Zhang, Xiao-Yan1; Li, Peng1; Han, Shuo1; Liu, Kai-Yu5; Zhang, Jin-Ming6; He, Qi-Hua7; Shen, Li1
关键词CD133 EGFRvIII Gefitinib resistance Stemness
刊名CNS NEUROSCIENCE & THERAPEUTICS
2013-07-01
DOI10.1111/cns.12092
19期:7页:494-502
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Neurosciences ; Pharmacology & Pharmacy
研究领域[WOS]Neurosciences & Neurology ; Pharmacology & Pharmacy
关键词[WOS]EPIDERMAL-GROWTH-FACTOR ; FACTOR RECEPTOR GENE ; CONFERS ENHANCED TUMORIGENICITY ; TYROSINE KINASE INHIBITOR ; TUMOR-INITIATING CELLS ; HUMAN-BRAIN TUMORS ; GLIOBLASTOMA-MULTIFORME ; ZD1839 IRESSA ; BREAST-CANCER ; HUMAN GLIOMAS
英文摘要

Aims To study the contribution of epidermal growth factor receptor variant III (EGFRvIII) to glioblastoma multiforme (GBM) stemness and gefitinib resistance. Methods CD133+ and CD133- cells were separated from EGFRvIII+ clinical specimens of three patients with newly diagnosed GBM. Then, RT-PCR was performed to evaluate EGFRvIII and EGFR expression in CD133+ and CD133- cells. The tumorigenicity and stemness of CD133+ cells was verified by intracranial implantation of 5x103 cells into immunodeficient NOD/SCID mice. Finally, cells were evaluated for their sensitivity to EGFR tyrosine kinase inhibition by gefitinib. Results RT-PCR results showed that the sorted CD133+ cells expressed EGFRvIII exclusively, while the CD133- cells expressed both EGFRvIII and EGFR. At 6-8weeks postimplantation, CD133+/EGFRvIII+/EGFR- cells formed intracranial tumors. Cell counting kit-8 results showed that the IC50 values of the three isolated EGFRvIII+ cell lines treated with gefitinib were 14.44, 16.00, and 14.66M, respectively, whereas the IC50 value of an isolated EGFRvIII- cell line was 8.57M. Conclusions EGFRvIII contributes to the stemness of cancer stem cells through coexpression with CD133 in GBMs. Furthermore, CD133+/EGFRvIII+/EGFR- cells have the ability to initiate tumor formation and may contribute to gefitinib resistance.

语种英语
WOS记录号WOS:000320197500004
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60227
专题北京大学基础医学院_细胞生物学系
北京大学医学部管理机构_医学部
作者单位1.PLA China, Navy Gen Hosp, Beijing, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Dept Cell Biol, Beijing 100871, Peoples R China
3.Beijing Union Med Coll Hosp, Beijing, Peoples R China
4.Beijing PLA, Mil Gen Hosp, Affiliated Bayi Brain Hosp, Beijing, Peoples R China
5.Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100871, Peoples R China
6.Peoples Liberat Army Gen Hosp, Dept Nucl Med, Beijing, Peoples R China
7.Peking Univ, Med & Hlth Anal Ctr, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Liu, Xu-Jie,Wu, Wen-Tao,Wu, Wei-Hua,et al. A Minority Subpopulation of CD133+/EGFRvIII+/EGFR- Cells Acquires Stemness and Contributes to Gefitinib Resistance[J]. CNS NEUROSCIENCE & THERAPEUTICS,2013,19(7):494-502.
APA Liu, Xu-Jie.,Wu, Wen-Tao.,Wu, Wei-Hua.,Yin, Feng.,Ma, Si-Hai.,...&Shen, Li.(2013).A Minority Subpopulation of CD133+/EGFRvIII+/EGFR- Cells Acquires Stemness and Contributes to Gefitinib Resistance.CNS NEUROSCIENCE & THERAPEUTICS,19(7),494-502.
MLA Liu, Xu-Jie,et al."A Minority Subpopulation of CD133+/EGFRvIII+/EGFR- Cells Acquires Stemness and Contributes to Gefitinib Resistance".CNS NEUROSCIENCE & THERAPEUTICS 19.7(2013):494-502.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Xu-Jie]的文章
[Wu, Wen-Tao]的文章
[Wu, Wei-Hua]的文章
百度学术
百度学术中相似的文章
[Liu, Xu-Jie]的文章
[Wu, Wen-Tao]的文章
[Wu, Wei-Hua]的文章
必应学术
必应学术中相似的文章
[Liu, Xu-Jie]的文章
[Wu, Wen-Tao]的文章
[Wu, Wei-Hua]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。